Comparación entre tenecteplase y alteplase en la trombolisis intravenosa del ataque cerebrovascular isquémico

Inés Rodríguez; Pedro Grille; Alberto Deicas

doi:10.29193/RMU.40.2.2

Authors

Inés Rodríguez CASMU- IAMPP, Medicina Intensiva, Médica residente https://orcid.org/0000-0002-6544-971X
Pedro Grille CASMU-IAMPP, Médico intensivista https://orcid.org/0000-0002-2099-4378
Alberto Deicas CASMU-IAMPP, Medicina Intensiva, Médico jefe https://orcid.org/0009-0006-5437-1861

DOI:

https://doi.org/10.29193/RMU.40.2.2

Keywords:

STROKE, THROMBOLYTIC THERAPY, ALTEPLASE, TENECTEPLASE

Abstract

Introduction: intravenous thrombolysis is a key part of the acute treatment of patients with ischemic stroke. There is a growing interest in the use of tenecteplase as a thrombolytic alternative to alteplase. The aim of this study is to compare the clinical effectiveness of tenecteplase versus alteplase in intravenous thrombolysis for ischemic stroke.
Method: a single-center, bispective cohort study of all patients admitted with ischemic stroke who received intravenous thrombolytics from 2019 to 2022. Patients treated with tenecteplase were prospectively compared with those treated with alteplase as a historical control. Chi-square or Fisher’s exact test was used for the association of categorical variables, and the Wilcoxon test was used for median comparison A p-value of less than 0.05 was considered significant.
Results: a total of 69 patients were included in the study (33 received alteplase and 36 received tenecteplase). The median NIHSS scale score was 11 (IQR 8-18), and the median time from symptom onset to needle was 160 minutes (IQR 120-208). No statistically significant differences were found between Glasgow Coma Scale and NIHSS scores at hospital discharge, as well as in modified Rankin Scale (mRS) 0-2 and mortality at 6 months, between the two groups of patients. There were also no differences in intracranial hemorrhagic complications between both groups (13.9% for tenecteplase and 12.1% for alteplase).
Conclusions: This is the first study on the topic in our setting. In line with recent international trials, our study did not show significant differences in clinical outcomes of patients treated with tenecteplase or alteplase. Tenecteplase could be a reasonable alternative to alteplase as thrombolytic therapy in ischemic stroke, with a good cost-benefit ratio and simpler implementation. Randomized studies with a larger number of patients are needed.

References

Comisión Honoraria para la Salud Cardiovascular. Informe de mortalidad por enfermedades del sistema circulatorio en Uruguay, 2022. Montevideo: CHSCV, 2022. Disponible en: https://cardiosalud.org/informemortalidad2022 (Consulta: 24 setiembre 2023).

Powers W, Rabinstein A, Ackerson T, Adeoye O, Bambakidis N, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2019; 50(12):e344-e418. doi: 10.1161/STR.0000000000000211.

von Kummer R, Broderick J, Campbell B, Demchuk A, Goyal M, Hill M, et al. The Heidelberg Bleeding Classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke 2015; 46(10):2981-6. doi: 10.1161/STROKEAHA.115.010049.

Forry J, Chappell A. Tenecteplase: a review of its pharmacology and uses. AACN Adv Crit Care 2023; 34(2):77-83. doi: 10.4037/aacnacc2023558.

Campbell B, Mitchell P, Churilov L, Yassi N, Kleinig T, Yan B, et al. Tenecteplase versus alteplase before endovascular thrombectomy (EXTEND-IA TNK): a multicenter, randomized, controlled study. Int J Stroke 2018; 13(3):328-34. doi: 10.1177/1747493017733935.

Logallo N, Novotny V, Assmus J, Kvistad C, Alteheld L, Ronning O, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet Neurol 2017; 16(10):781-8. doi: 10.1016/S1474-4422(17)30253-3.

Kvistad C, Næss H, Helleberg B, Idicula T, Hagberg G, Nordby L, et al. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. Lancet Neurol 2022; 21(6):511-9. doi: 10.1016/S1474-4422(22)00124-7.

Menon B, Buck B, Singh N, Deschaintre Y, Almekhlafi M, Coutts S, et al. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial. Lancet 2022; 400(10347):161-9. doi: 10.1016/S0140-6736(22)01054-6.

Wang Y, Li S, Pan Y, Li H, Parsons M, Campbell B, et al. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial. Lancet 2023; 401(10377):645-54. doi: 10.1016/S0140-6736(22)02600-9.

Alamowitch S, Turc G, Palaiodimou L, Bivard A, Cameron A, De Marchis G, et al. European Stroke Organisation (ESO) expedited recommendation on tenecteplase for acute ischaemic stroke. Eur Stroke J 2023; 8(1):8-54. doi: 10.1177/23969873221150022.

Gaye A, Camejo C, Amorín I, Orellana C, Prinzo H, Ferrando R, et al. Protocolo Nacional de ACV. Uruguay 2020. Montevideo: MSP, 2020. Disponible en: https://www.gub.uy/ministerio-salud-publica/comunicacion/publicaciones/protocolo-nacional-acv (Consulta: 24 setiembre 2023).

Teasdale G, Jennett B. Assessment of coma and impaired consciousness: a practical scale. Lancet 1974; 2(7872):81-4. doi: 10.1016/s0140-6736(74)91639-0.

Brott T, Adams HJr, Olinger C, Marler J, Barsan W, Biller J, et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 1989; 20(7):864-70. doi: 10.1161/01.str.20.7.864.

Banks J, Marotta C. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 2007; 38(3):1091-6. doi: 10.1161/01.STR.0000258355.23810.c6.

Murphy L, Hill T, Paul K, Talbott M, Golovko G, Shaltoni H, et al. Tenecteplase versus alteplase for acute stroke: mortality and bleeding complications. Ann Emerg Med 2023; 82(6):720-8. doi: 10.1016/j.annemergmed.2023.03.022.

Warach S, Ranta A, Kim J, Song S, Wallace A, Beharry J, et al. Symptomatic intracranial hemorrhage with tenecteplase vs alteplase in patients with acute ischemic stroke: the Comparative Effectiveness of Routine Tenecteplase vs Alteplase in Acute Ischemic Stroke (CERTAIN) Collaboration. JAMA Neurol 2023; 80(7):732-8. doi: 10.1001/jamaneurol.2023.1449.

Brunet F, Camejo C, Gaye A, Castro L, Puppo C, Niggemeyer A, et al. Ataque cerebrovascular isquémico en Uruguay: comunicación de los primeros 34 casos trombolizados en el Hospital de Clínicas. Rev Méd Urug 2014; 30(1):37-48. Disponible en: http://www.scielo.edu.uy/pdf/rmu/v30n1/v30n1a05.pdf (Consulta: 24 setiembre 2023).

Gaye A, Méndez T, Décima R, Vidal J, Pérez G, Preve F, et al. Nuevos paradigmas: 12 años de trombólisis sistémica. Unidad de ACV, Hospital de Clínicas. Rev Méd Urug 2023; 39(1):e202. doi: 10.29193/rmu.39.1.2.

Shen Z, Bao N, Tang M, Yang Y, Li J, Liu W, et al. Tenecteplase vs. alteplase for intravenous thrombolytic therapy of acute ischemic stroke: a systematic review and meta-analysis. Neurol Ther 2023; 12(5):1553-72. doi: 10.1007/s40120-023-00530-4.